{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:08:17Z","timestamp":1776107297587,"version":"3.50.1"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T00:00:00Z","timestamp":1553299200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40265-019-01098-w","type":"journal-article","created":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T09:03:36Z","timestamp":1553331816000},"page":"593-608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Contemporary Options for the Management of Motor Complications in Parkinson\u2019s Disease: Updated Clinical Review"],"prefix":"10.1007","volume":"79","author":[{"given":"Ver\u00f3nica","family":"Cabreira","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2446-5078","authenticated-orcid":false,"given":"Patr\u00edcio","family":"Soares-da-Silva","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5791-7149","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Massano","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,3,23]]},"reference":[{"issue":"8","key":"1098_CR1","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/oxfordjournals.aje.a117721","volume":"142","author":"R Mayeux","year":"1995","unstructured":"Mayeux R, Marder K, Cote LJ, Denaro J, Hemenegildo N, Mejia H, et al. The frequency of idiopathic Parkinson\u2019s disease by age, ethnic group, and sex in northern Manhattan, 1988\u20131993. Am J Epidemiol. 1995;142(8):820\u20137.","journal-title":"Am J Epidemiol"},{"issue":"9680","key":"1098_CR2","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","volume":"373","author":"AJ Lees","year":"2009","unstructured":"Lees AJ, Hardy J, Revesz T. Parkinson\u2019s disease. Lancet. 2009;373(9680):2055\u201366. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(09)60492-X\n                    \n                  .","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1098_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1468-1331.2008.02056.x","volume":"15","author":"W Poewe","year":"2008","unstructured":"Poewe W. Non-motor symptoms in Parkinson\u2019s disease. Eur J Neurol. 2008;15(Suppl 1):14\u201320. \n                    https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02056.x\n                    \n                  .","journal-title":"Eur J Neurol"},{"key":"1098_CR4","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/j.1468-1331.2009.02697.x","volume":"16","author":"AHV Schapira","year":"2009","unstructured":"Schapira AHV, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinson\u2019s disease. Eur J Neurol. 2009;16:982\u20139. \n                    https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02697.x\n                    \n                  .","journal-title":"Eur J Neurol"},{"issue":"6645","key":"1098_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839\u201340. \n                    https:\/\/doi.org\/10.1038\/42166\n                    \n                  .","journal-title":"Nature"},{"issue":"4","key":"1098_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.1969.00480160015001","volume":"21","author":"M Yahr","year":"1969","unstructured":"Yahr M, Duvoisin R, Schear M, Barrett R, Hoehn M. Treatment of parkinsonism with levodopa. Arch Neurol. 1969;21(4):343\u201354.","journal-title":"Arch Neurol"},{"issue":"7","key":"1098_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJM196902132800701","volume":"280","author":"GC Cotzias","year":"1969","unstructured":"Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism\u2014chronic treatment with l-dopa. N Engl J Med. 1969;280(7):337\u201345. \n                    https:\/\/doi.org\/10.1056\/NEJM196902132800701\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"4","key":"1098_CR8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J. Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368\u201376. \n                    https:\/\/doi.org\/10.1136\/jnnp.2007.131045\n                    \n                  .","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"1098_CR9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2165\/00023210-200721080-00005","volume":"21","author":"J Jankovic","year":"2007","unstructured":"Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson\u2019s disease. CNS Drugs. 2007;21(8):677\u201392. \n                    https:\/\/doi.org\/10.2165\/00023210-200721080-00005\n                    \n                  .","journal-title":"CNS Drugs"},{"issue":"5","key":"1098_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000300647","volume":"63","author":"F Stocchi","year":"2010","unstructured":"Stocchi F, Jenner P, Obeso JA. When do levodopa motor fluctuations first appear in Parkinson\u2019s disease? Eur Neurol. 2010;63(5):257\u201366. \n                    https:\/\/doi.org\/10.1159\/000300647\n                    \n                  .","journal-title":"Eur Neurol"},{"issue":"3","key":"1098_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448\u201358. \n                    https:\/\/doi.org\/10.1002\/mds.1090\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"5","key":"1098_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1468-1331.2008.02106.x","volume":"15","author":"JC Sharma","year":"2008","unstructured":"Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur J Neurol. 2008;15(5):493\u20136. \n                    https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02106.x\n                    \n                  .","journal-title":"Eur J Neurol"},{"issue":"8","key":"1098_CR13","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mds.25364","volume":"28","author":"C Warren Olanow","year":"2013","unstructured":"Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson\u2019s disease. Mov Disord. 2013;28(8):1064\u201371. \n                    https:\/\/doi.org\/10.1002\/mds.25364\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"1098_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jns.2012.05.010","volume":"319","author":"H Doi","year":"2012","unstructured":"Doi H, Sakakibara R, Sato M, Masaka T, Kishi M, Tateno A, et al. Plasma levodopa peak delay and impaired gastric emptying in Parkinson\u2019s disease. J Neurol Sci. 2012;319(1\u20132):86\u20138. \n                    https:\/\/doi.org\/10.1016\/j.jns.2012.05.010\n                    \n                  .","journal-title":"J Neurol Sci"},{"issue":"1","key":"1098_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/mds.26125","volume":"30","author":"CC Aquino","year":"2015","unstructured":"Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord. 2015;30(1):80\u20139. \n                    https:\/\/doi.org\/10.1002\/mds.26125\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"6","key":"1098_CR16","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/mds.27340","volume":"33","author":"A Antonini","year":"2018","unstructured":"Antonini A, Moro E, Godeiro C, Reichmann H. Medical and surgical management of advanced Parkinson\u2019s disease. Mov Disord. 2018;33(6):900\u20138. \n                    https:\/\/doi.org\/10.1002\/mds.27340\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"24","key":"1098_CR17","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med. 2004;351(24):2498\u2013508. \n                    https:\/\/doi.org\/10.1056\/NEJMoa033447\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"9949","key":"1098_CR18","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/s0140-6736(14)60683-8","volume":"384","author":"R Gray","year":"2014","unstructured":"PD Med Collaborative Group, Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196\u2013205. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(14)60683-8\n                    \n                  .","journal-title":"Lancet"},{"issue":"4","key":"1098_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1056\/NEJMoa1809983","volume":"380","author":"CVM Verschuur","year":"2019","unstructured":"Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ, et al. Randomized delayed-start trial of levodopa in Parkinson\u2019s disease. N Engl J Med. 2019;380(4):315\u201324. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1809983\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"4","key":"1098_CR20","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1212\/WNL.39.4.552","volume":"39","author":"J Carter","year":"1989","unstructured":"Carter J, Nutt J, Woodward W, Hatcher L, Trotman T. Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson\u2019s disease. Neurology. 1989;39(4):552\u20136.","journal-title":"Neurology"},{"issue":"8","key":"1098_CR21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1056\/NEJM198402233100802","volume":"310","author":"J Nutt","year":"1984","unstructured":"Nutt J, Woodward W, Hammerstad J, Carter J, Anderson J. The, \u201con\u2013off\u201d phenomenon in Parkinson\u2019s disease. Relation to levodopa absorption and transport. N Engl J Med. 1984;310(8):483\u20138.","journal-title":"N Engl J Med"},{"issue":"206","key":"1098_CR22","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3389\/fnagi.2017.00206","volume":"9","author":"L Wang","year":"2017","unstructured":"Wang L, Xiong N, Huang J, Guo S, Liu L, Han C, et al. Protein-restricted diets for ameliorating motor fluctuations in Parkinson\u2019s disease. Front Aging Neurosci. 2017;9(206):1663\u20134365. \n                    https:\/\/doi.org\/10.3389\/fnagi.2017.00206\n                    \n                  .","journal-title":"Front Aging Neurosci"},{"issue":"13","key":"1098_CR23","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/mds.23226","volume":"25","author":"E Cereda","year":"2010","unstructured":"Cereda E, Barichella M, Pedrolli C, Pezzoli G. Low-protein and protein-redistribution diets for Parkinson\u2019s disease patients with motor fluctuations: a systematic review. Mov Disord. 2010;25(13):2021\u201334. \n                    https:\/\/doi.org\/10.1002\/mds.23226\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"9","key":"1098_CR24","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40262-017-0511-y","volume":"56","author":"A Mittur","year":"2017","unstructured":"Mittur A, Gupta S, Modi NB. Pharmacokinetics of Rytary((R)), an extended-release capsule formulation of carbidopa\u2013levodopa. Clin Pharmacokinet. 2017;56(9):999\u20131014. \n                    https:\/\/doi.org\/10.1007\/s40262-017-0511-y\n                    \n                  .","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1098_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/WNF.0000000000000126","volume":"39","author":"HM Yao","year":"2016","unstructured":"Yao HM, Hsu A, Gupta S, Modi NB. Clinical pharmacokinetics of IPX066: evaluation of dose proportionality and effect of food in healthy volunteers. Clin Neuropharmacol. 2016;39(1):10\u20137. \n                    https:\/\/doi.org\/10.1097\/WNF.0000000000000126\n                    \n                  .","journal-title":"Clin Neuropharmacol"},{"key":"1098_CR26","doi-asserted-by":"publisher","first-page":"9763057","DOI":"10.1155\/2018\/9763057","volume":"2018","author":"JC Morgan","year":"2018","unstructured":"Morgan JC, Dhall R, Rubens R, Khanna S, Gupta S. Dosing patterns during conversion to IPX066, extended-release carbidopa\u2013levodopa (ER CD-LD), in Parkinson\u2019s disease with motor fluctuations. Parkinsons Dis. 2018;2018:9763057. \n                    https:\/\/doi.org\/10.1155\/2018\/9763057\n                    \n                  .","journal-title":"Parkinsons Dis"},{"issue":"2","key":"1098_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.parkreldis.2013.08.017","volume":"20","author":"R Pahwa","year":"2014","unstructured":"Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, et al. Randomized trial of IPX066, carbidopa\/levodopa extended release, in early Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20(2):142\u20138. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2013.08.017\n                    \n                  .","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"1098_CR28","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1474-4422(13)70025-5","volume":"12","author":"RA Hauser","year":"2013","unstructured":"Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, et al. Extended-release carbidopa\u2013levodopa (IPX066) compared with immediate-release carbidopa\u2013levodopa in patients with Parkinson\u2019s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12(4):346\u201356. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(13)70025-5\n                    \n                  .","journal-title":"Lancet Neurol"},{"issue":"12","key":"1098_CR29","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.parkreldis.2014.08.004","volume":"20","author":"F Stocchi","year":"2014","unstructured":"Stocchi F, Hsu A, Khanna S, Ellenbogen A, Mahler A, Liang G, et al. Comparison of IPX066 with carbidopa\u2013levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord. 2014;20(12):1335\u201340. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2014.08.004\n                    \n                  .","journal-title":"Parkinsonism Relat Disord"},{"issue":"14 Suppl 1","key":"1098_CR30","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1212\/WNL.0000000000002510","volume":"86","author":"R Dhall","year":"2016","unstructured":"Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology. 2016;86(14 Suppl 1):S13\u201324. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000002510\n                    \n                  .","journal-title":"Neurology"},{"issue":"11","key":"1098_CR31","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/mds.26362","volume":"30","author":"O Rascol","year":"2015","unstructured":"Rascol O, Perez-Lloret S, Ferreira JJ. New treatments for levodopa-induced motor complications. Mov Disord. 2015;30(11):1451\u201360. \n                    https:\/\/doi.org\/10.1002\/mds.26362\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"9","key":"1098_CR32","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/mds.26611","volume":"31","author":"PA LeWitt","year":"2016","unstructured":"LeWitt PA, Hauser RA, Grosset DG, Stocchi F, Saint-Hilaire MH, Ellenbogen A, et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson\u2019s disease. Mov Disord. 2016;31(9):1356\u201365. \n                    https:\/\/doi.org\/10.1002\/mds.26611\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"2","key":"1098_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","volume":"18","author":"PA LeWitt","year":"2019","unstructured":"LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18(2):145\u201354. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(18)30405-8\n                    \n                  .","journal-title":"Lancet Neurol"},{"issue":"10","key":"1098_CR34","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/mds.10508","volume":"18","author":"Y Mizuno","year":"2003","unstructured":"Mizuno Y, Yanagisawa N, Kuno S, Yamamoto M, Hasegawa K, Origasa H, et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson\u2019s disease. Mov Disord. 2003;18(10):1149\u201356. \n                    https:\/\/doi.org\/10.1002\/mds.10508\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"5","key":"1098_CR35","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/mds.20397","volume":"20","author":"JC Moller","year":"2005","unstructured":"Moller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson\u2019s disease: results from a European multicenter trial. Mov Disord. 2005;20(5):602\u201310. \n                    https:\/\/doi.org\/10.1002\/mds.20397\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"4","key":"1098_CR36","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1212\/WNL.51.4.1057","volume":"51","author":"A Lieberman","year":"1998","unstructured":"Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson\u2019s disease. Ropinirole Study Group. Neurology. 1998;51(4):1057\u201362.","journal-title":"Neurology"},{"issue":"8","key":"1098_CR37","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2018;33(8):1248\u201366. \n                    https:\/\/doi.org\/10.1002\/mds.27372\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"12","key":"1098_CR38","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.parkreldis.2014.10.005","volume":"20","author":"Y Mizuno","year":"2014","unstructured":"Mizuno Y, Nomoto M, Hasegawa K, Hattori N, Kondo T, Murata M, et al. Rotigotine vs ropinirole in advanced stage Parkinson\u2019s disease: a double-blind study. Parkinsonism Relat Disord. 2014;20(12):1388\u201393. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2014.10.005\n                    \n                  .","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"1098_CR39","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","volume":"6","author":"WH Poewe","year":"2007","unstructured":"Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6(6):513\u201320. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(07)70108-4\n                    \n                  .","journal-title":"Lancet Neurol"},{"issue":"2","key":"1098_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.baga.2012.05.009","volume":"2","author":"C Trenkwalder","year":"2012","unstructured":"Trenkwalder C, Kies B, Dioszeghy P, Hill D, Surmann E, Boroojerdi B, et al. Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson\u2019s disease: results from a 1-year, open-label extension of the RECOVER study. Basal Ganglia. 2012;2(2):79\u201385. \n                    https:\/\/doi.org\/10.1016\/j.baga.2012.05.009\n                    \n                  .","journal-title":"Basal Ganglia"},{"issue":"1","key":"1098_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90\u20139. \n                    https:\/\/doi.org\/10.1002\/mds.23441\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"7","key":"1098_CR42","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/mds.23498","volume":"26","author":"F Stocchi","year":"2011","unstructured":"Stocchi F, Giorgi L, Hunter B, Schapira AH. PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson\u2019s disease. Mov Disord. 2011;26(7):1259\u201365. \n                    https:\/\/doi.org\/10.1002\/mds.23498\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"8","key":"1098_CR43","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1212\/WNL.0b013e31822affb0","volume":"77","author":"W Poewe","year":"2011","unstructured":"Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, et al. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology. 2011;77(8):759\u201366. \n                    https:\/\/doi.org\/10.1212\/WNL.0b013e31822affb0\n                    \n                  .","journal-title":"Neurology"},{"issue":"18","key":"1098_CR44","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1007\/s40265-014-0322-5","volume":"74","author":"JE Frampton","year":"2014","unstructured":"Frampton JE. Pramipexole extended-release: a review of its use in patients with Parkinson\u2019s disease. Drugs. 2014;74(18):2175\u201390. \n                    https:\/\/doi.org\/10.1007\/s40265-014-0322-5\n                    \n                  .","journal-title":"Drugs"},{"issue":"16","key":"1098_CR45","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/mds.21743","volume":"22","author":"RA Hauser","year":"2007","unstructured":"Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, et al. Ten-year follow-up of Parkinson\u2019s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007;22(16):2409\u201317. \n                    https:\/\/doi.org\/10.1002\/mds.21743\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"2","key":"1098_CR46","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/mdc3.12141","volume":"2","author":"KR Chaudhuri","year":"2015","unstructured":"Chaudhuri KR, Todorova A, Nirenberg MJ, Parry M, Martin A, Martinez-Martin P, et al. A pilot prospective, multicenter observational study of dopamine agonist withdrawal syndrome in Parkinson\u2019s disease. Mov Disord Clin Pract. 2015;2(2):170\u20134. \n                    https:\/\/doi.org\/10.1002\/mdc3.12141\n                    \n                  .","journal-title":"Mov Disord Clin Pract"},{"issue":"8","key":"1098_CR47","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40266-013-0090-z","volume":"30","author":"MJ Nirenberg","year":"2013","unstructured":"Nirenberg MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging. 2013;30(8):587\u201392. \n                    https:\/\/doi.org\/10.1007\/s40266-013-0090-z\n                    \n                  .","journal-title":"Drugs Aging"},{"key":"1098_CR48","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jns.2017.06.022","volume":"379","author":"S Patel","year":"2017","unstructured":"Patel S, Garcia X, Mohammad ME, Yu XX, Vlastaris K, O\u2019Donnell K, et al. Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment center. J Neurol Sci. 2017;379:308\u201311. \n                    https:\/\/doi.org\/10.1016\/j.jns.2017.06.022\n                    \n                  .","journal-title":"J Neurol Sci"},{"issue":"1","key":"1098_CR49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/archneurol.2009.294","volume":"67","author":"CA Rabinak","year":"2010","unstructured":"Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58\u201363. \n                    https:\/\/doi.org\/10.1001\/archneurol.2009.294\n                    \n                  .","journal-title":"Arch Neurol"},{"issue":"1","key":"1098_CR50","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med. 2007;356(1):39\u201346. \n                    https:\/\/doi.org\/10.1056\/NEJMoa054830\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"5","key":"1098_CR51","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.parkreldis.2012.03.003","volume":"18","author":"PR Fitzsimmons","year":"2012","unstructured":"Fitzsimmons PR, Blayney S, Mina-Corkill S, Scott GO. Older participants are frequently excluded from Parkinson\u2019s disease research. Parkinsonism Relat Disord. 2012;18(5):585\u20139. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2012.03.003\n                    \n                  .","journal-title":"Parkinsonism Relat Disord"},{"key":"1098_CR52","doi-asserted-by":"publisher","first-page":"CD006564","DOI":"10.1002\/14651858.cd006564.pub2","volume":"2","author":"RL Stowe","year":"2008","unstructured":"Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, et al. Dopamine agonist therapy in early Parkinson\u2019s disease. Cochrane Database Syst Rev. 2008;2:CD006564. \n                    https:\/\/doi.org\/10.1002\/14651858.cd006564.pub2\n                    \n                  .","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1098_CR53","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/01.nrl.0000215782.78763.fa","volume":"12","author":"D Silver","year":"2006","unstructured":"Silver D. Impact of functional age on the use of dopamine agonists in patients with Parkinson disease. Neurologist. 2006;12(4):214\u201323.","journal-title":"Neurologist"},{"issue":"7","key":"1098_CR54","doi-asserted-by":"publisher","first-page":"e00453","DOI":"10.1002\/brb3.453","volume":"6","author":"ES Castro","year":"2016","unstructured":"Castro ES, Santos-Garcia D, de Deus Fonticoba T, Exposito Ruiz I, Tunas Gesto C, Arribi MM. Causes and factors related to dopamine agonist withdrawal in Parkinson\u2019s disease. Brain Behav. 2016;6(7):e00453. \n                    https:\/\/doi.org\/10.1002\/brb3.453\n                    \n                  .","journal-title":"Brain Behav"},{"issue":"4","key":"1098_CR55","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/1531-8257(200007)15:4<664::AID-MDS1010>3.0.CO;2-D","volume":"15","author":"L Shulman","year":"2000","unstructured":"Shulman L, Minagar A, Rabinstein A, Weiner W. The use of dopamine agonists in very elderly patients with Parkinson\u2019s disease. Mov Disord. 2000;15(4):664\u20138.","journal-title":"Mov Disord"},{"issue":"1","key":"1098_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3109\/00207454.2014.991924","volume":"126","author":"CW Makumi","year":"2016","unstructured":"Makumi CW, Asgharian A, Ellis J, Shaikh S, Jimenez T, VanMeter S. Long-term, open-label, safety study of once-daily ropinirole extended\/prolonged release in early and advanced Parkinson\u2019s disease. Int J Neurosci. 2016;126(1):30\u20138. \n                    https:\/\/doi.org\/10.3109\/00207454.2014.991924\n                    \n                  .","journal-title":"Int J Neurosci"},{"issue":"7","key":"1098_CR57","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/01.wnl.0000310812.43352.66","volume":"71","author":"R Katzenschlager","year":"2008","unstructured":"Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology. 2008;71(7):474\u201380. \n                    https:\/\/doi.org\/10.1212\/01.wnl.0000310812.43352.66\n                    \n                  .","journal-title":"Neurology"},{"issue":"2","key":"1098_CR58","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.20324","volume":"20","author":"MA Hely","year":"2005","unstructured":"Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson\u2019s disease: non-l-dopa-responsive problems dominate at 15\u00a0years. Mov Disord. 2005;20(2):190\u20139. \n                    https:\/\/doi.org\/10.1002\/mds.20324\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"9","key":"1098_CR59","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/mds.21292","volume":"22","author":"R Constantinescu","year":"2007","unstructured":"Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K, Group C-PIotPS. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord. 2007;22(9):1317\u20139. \n                    https:\/\/doi.org\/10.1002\/mds.21292\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"12","key":"1098_CR60","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s00702-015-1449-6","volume":"122","author":"M Kuoppamaki","year":"2015","unstructured":"Kuoppamaki M, Leinonen M, Poewe W. Efficacy and safety of entacapone in levodopa\/carbidopa versus levodopa\/benserazide treated Parkinson\u2019s disease patients with wearing-off. J Neural Transm (Vienna). 2015;122(12):1709\u201314. \n                    https:\/\/doi.org\/10.1007\/s00702-015-1449-6\n                    \n                  .","journal-title":"J Neural Transm (Vienna)"},{"issue":"5","key":"1098_CR61","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","volume":"51","author":"UK Rinne","year":"1998","unstructured":"Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology. 1998;51(5):1309\u201314. \n                    https:\/\/doi.org\/10.1212\/WNL.51.5.1309\n                    \n                  .","journal-title":"Neurology"},{"issue":"4","key":"1098_CR62","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","volume":"105","author":"WH Poewe","year":"2002","unstructured":"Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M, Celomen Study Group. Efficacy and safety of entacapone in Parkinson\u2019s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002;105(4):245\u201355. \n                    https:\/\/doi.org\/10.1034\/j.1600-0404.2002.1o174.x\n                    \n                  .","journal-title":"Acta Neurol Scand"},{"issue":"8","key":"1098_CR63","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","volume":"74","author":"DJ Brooks","year":"2003","unstructured":"Brooks DJ. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson\u2019s disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003;74(8):1071\u20139. \n                    https:\/\/doi.org\/10.1136\/jnnp.74.8.1071\n                    \n                  .","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1098_CR64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/WNF.0b013e318241520b","volume":"35","author":"O Rascol","year":"2012","unstructured":"Rascol O, Barone P, Behari M, Emre M, Giladi N, Olanow CW, et al. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin Neuropharmacol. 2012;35(1):15\u201320. \n                    https:\/\/doi.org\/10.1097\/WNF.0b013e318241520b\n                    \n                  .","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"1098_CR65","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ana.22060","volume":"68","author":"F Stocchi","year":"2010","unstructured":"Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, et al. Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18\u201327. \n                    https:\/\/doi.org\/10.1002\/ana.22060\n                    \n                  .","journal-title":"Ann Neurol"},{"issue":"4","key":"1098_CR66","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00702-013-1114-x","volume":"121","author":"E Tolosa","year":"2014","unstructured":"Tolosa E, Hernandez B, Linazasoro G, Lopez-Lozano JJ, Mir P, Marey J, et al. Efficacy of levodopa\/carbidopa\/entacapone versus levodopa\/carbidopa in patients with early Parkinson\u2019s disease experiencing mild wearing-off: a randomised, double-blind trial. J Neural Transm (Vienna). 2014;121(4):357\u201366. \n                    https:\/\/doi.org\/10.1007\/s00702-013-1114-x\n                    \n                  .","journal-title":"J Neural Transm (Vienna)"},{"issue":"5","key":"1098_CR67","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/mds.26140","volume":"30","author":"P Korhonen","year":"2015","unstructured":"Korhonen P, Kuoppamaki M, Prami T, Hoti F, Christopher S, Ellmen J, et al. Entacapone and prostate cancer risk in patients with Parkinson\u2019s disease. Mov Disord. 2015;30(5):724\u20138. \n                    https:\/\/doi.org\/10.1002\/mds.26140\n                    \n                  .","journal-title":"Mov Disord"},{"key":"1098_CR68","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.parkreldis.2018.04.035","volume":"53","author":"JM Major","year":"2018","unstructured":"Major JM, Dong D, Cunningham F, By K, Hur K, Shih DC, et al. Entacapone and prostate cancer in Parkinson\u2019s disease patients: a large Veterans Affairs healthcare system study. Parkinsonism Relat Disord. 2018;53:46\u201352.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"1098_CR69","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/s1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Lees A, Rocha J-F, Poewe W, Rascol O, Soares-da-Silva P. Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15(2):154\u201365. \n                    https:\/\/doi.org\/10.1016\/s1474-4422(15)00336-1\n                    \n                  .","journal-title":"Lancet Neurol"},{"issue":"5","key":"1098_CR70","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/ene.12666","volume":"22","author":"JJ Ferreira","year":"2015","unstructured":"Ferreira JJ, Rocha JF, Falcao A, Santos A, Pinto R, Nunes T, et al. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson\u2019s disease. Eur J Neurol. 2015;22(5):815\u2013825, e56. \n                    https:\/\/doi.org\/10.1111\/ene.12666\n                    \n                  .","journal-title":"Eur J Neurol"},{"issue":"2","key":"1098_CR71","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","volume":"74","author":"AJ Lees","year":"2017","unstructured":"Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74(2):197\u2013206. \n                    https:\/\/doi.org\/10.1001\/jamaneurol.2016.4703\n                    \n                  .","journal-title":"JAMA Neurol"},{"key":"1098_CR72","unstructured":"Ferreira J, Poewe W, Rascol O, Costa R, Arbe E, Rocha J, et al. Relationship between patient global impression of change and other efficacy endpoints in Parkinson\u2019s disease: a post-hoc analysis from combined BIPARK-I and II [abstract]. Mov Disord. 2018; 33 (suppl 2). \n                    https:\/\/www.mdsabstracts.org\/abstract\/relationship-between-patient-global-impression-of-change-and-other-efficacy-endpoints-in-parkinsons-disease-a-post-hoc-analysis-from-combined-bipark-i-and-ii\/\n                    \n                  . Accessed March 8, 2019."},{"issue":"2","key":"1098_CR73","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1046\/j.1468-1331.2003.00559.x","volume":"10","author":"JP Larsen","year":"2003","unstructured":"Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M, et al. The tolerability and efficacy of entacapone over 3\u00a0years in patients with Parkinson\u2019s disease. Eur J Neurol. 2003;10(2):137\u201346. \n                    https:\/\/doi.org\/10.1046\/j.1468-1331.2003.00559.x\n                    \n                  .","journal-title":"Eur J Neurol"},{"issue":"11","key":"1098_CR74","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.parkreldis.2013.06.001","volume":"19","author":"LW Elmer","year":"2013","unstructured":"Elmer LW. Rasagiline adjunct therapy in patients with Parkinson\u2019s disease: post hoc analyses of the PRESTO and LARGO trials. Parkinsonism Relat Disord. 2013;19(11):930\u20136. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2013.06.001\n                    \n                  .","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"1098_CR75","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archneur.62.2.241","volume":"62","author":"Parkinson Study Group","year":"2005","unstructured":"Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62(2):241\u20138. \n                    https:\/\/doi.org\/10.1001\/archneur.62.2.241\n                    \n                  .","journal-title":"Arch Neurol"},{"issue":"9463","key":"1098_CR76","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/s0140-6736(05)71083-7","volume":"365","author":"O Rascol","year":"2005","unstructured":"Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365(9463):947\u201354. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(05)71083-7\n                    \n                  .","journal-title":"Lancet"},{"issue":"4","key":"1098_CR77","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1212\/WNL.48.4.1070","volume":"48","author":"IH Richard","year":"1997","unstructured":"Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson\u2019s disease. Parkinson Study Group. Neurology. 1997;48(4):1070\u20137.","journal-title":"Neurology"},{"issue":"12","key":"1098_CR78","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/phar.1500","volume":"34","author":"M Panisset","year":"2014","unstructured":"Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J, STACCATO study investigators. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy. 2014;34(12):1250\u20138. \n                    https:\/\/doi.org\/10.1002\/phar.1500\n                    \n                  .","journal-title":"Pharmacotherapy"},{"key":"1098_CR79","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/B978-0-12-386467-3.00009-1","volume":"100","author":"JP Finberg","year":"2011","unstructured":"Finberg JP, Gillman K. Selective inhibitors of monoamine oxidase type B and the \u201ccheese effect\u201d. Int Rev Neurobiol. 2011;100:169\u201390. \n                    https:\/\/doi.org\/10.1016\/B978-0-12-386467-3.00009-1\n                    \n                  .","journal-title":"Int Rev Neurobiol"},{"issue":"2","key":"1098_CR80","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.25751","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations. Mov Disord. 2014;29(2):229\u201337. \n                    https:\/\/doi.org\/10.1002\/mds.25751\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"1","key":"1098_CR81","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/mds.23954","volume":"27","author":"F Stocchi","year":"2012","unstructured":"Stocchi F, Borgohain R, Onofrj M, Schapira AH, Bhatt M, Lucini V, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson\u2019s disease patients. Mov Disord. 2012;27(1):106\u201312. \n                    https:\/\/doi.org\/10.1002\/mds.23954\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"2","key":"1098_CR82","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","volume":"74","author":"AH Schapira","year":"2017","unstructured":"Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74(2):216\u201324. \n                    https:\/\/doi.org\/10.1001\/jamaneurol.2016.4467\n                    \n                  .","journal-title":"JAMA Neurol"},{"issue":"10","key":"1098_CR83","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/mds.26286","volume":"30","author":"M Murata","year":"2015","unstructured":"Murata M, Hasegawa K, Kanazawa I, Fukasaka J, Kochi K, Shimazu R, et al. Zonisamide improves wearing-off in Parkinson\u2019s disease: a randomized, double-blind study. Mov Disord. 2015;30(10):1343\u201350. \n                    https:\/\/doi.org\/10.1002\/mds.26286\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"2","key":"1098_CR84","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/wnf.0000000000000073","volume":"38","author":"T Kondo","year":"2015","unstructured":"Kondo T, Mizuno Y, Japanese Istradefylline Study Group. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. Clin Neuropharmacol. 2015;38(2):41\u20136. \n                    https:\/\/doi.org\/10.1097\/wnf.0000000000000073\n                    \n                  .","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"1098_CR85","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1517\/14740338.2015.988137","volume":"14","author":"M Pilleri","year":"2015","unstructured":"Pilleri M, Antonini A. Therapeutic strategies to prevent and manage dyskinesias in Parkinson\u2019s disease. Expert Opin Drug Saf. 2015;14(2):281\u201394. \n                    https:\/\/doi.org\/10.1517\/14740338.2015.988137\n                    \n                  .","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 4","key":"1098_CR86","first-page":"IV37","volume":"252","author":"S Fahn","year":"2005","unstructured":"Fahn S, Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson\u2019s disease? J Neurol. 2005;252(Suppl 4):IV37\u201342.","journal-title":"J Neurol."},{"issue":"Suppl 3","key":"1098_CR87","doi-asserted-by":"publisher","first-page":"S570","DOI":"10.1002\/mds.22019","volume":"23","author":"P Calabresi","year":"2008","unstructured":"Calabresi P, Di Filippo M, Ghiglieri V, Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord. 2008;23(Suppl 3):S570\u20139. \n                    https:\/\/doi.org\/10.1002\/mds.22019\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"6","key":"1098_CR88","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/mds.27172","volume":"33","author":"H Nishijima","year":"2018","unstructured":"Nishijima H, Ueno T, Funamizu Y, Ueno S, Tomiyama M. Levodopa treatment and dendritic spine pathology. Mov Disord. 2018;33(6):877\u201388. \n                    https:\/\/doi.org\/10.1002\/mds.27172\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"1","key":"1098_CR89","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/00002826-200001000-00007","volume":"23","author":"Parkinson Study Group","year":"2000","unstructured":"Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson\u2019s disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin Neuropharmacol. 2000;23(1):34\u201344.","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"1098_CR90","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/ana.10609","volume":"54","author":"AL Whone","year":"2003","unstructured":"Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson\u2019s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54(1):93\u2013101. \n                    https:\/\/doi.org\/10.1002\/ana.10609\n                    \n                  .","journal-title":"Ann Neurol"},{"issue":"20","key":"1098_CR91","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484\u201391. \n                    https:\/\/doi.org\/10.1056\/NEJM200005183422004\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"7","key":"1098_CR92","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1001\/archneur.61.7.1044","volume":"61","author":"RG Holloway","year":"2004","unstructured":"Holloway RG. Pramipexole vs levodopa as initial treatment for Parkinson disease. Arch Neurol. 2004;61(7):1044\u201353. \n                    https:\/\/doi.org\/10.1001\/archneur.61.7.1044\n                    \n                  .","journal-title":"Arch Neurol"},{"issue":"4","key":"1098_CR93","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/cns.12239","volume":"20","author":"CQ Zhou","year":"2014","unstructured":"Zhou CQ, Lou JH, Zhang YP, Zhong L, Chen YL, Lu FJ, et al. Long-acting versus standard non-ergot dopamine agonists in Parkinson\u2019s disease: a meta-analysis of randomized controlled trials. CNS Neurosci Ther. 2014;20(4):368\u201376. \n                    https:\/\/doi.org\/10.1111\/cns.12239\n                    \n                  .","journal-title":"CNS Neurosci Ther"},{"issue":"34","key":"1098_CR94","doi-asserted-by":"publisher","first-page":"e11316","DOI":"10.1097\/MD.0000000000011316","volume":"97","author":"Z Shen","year":"2018","unstructured":"Shen Z, Kong D. Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease. Medicine (Baltimore). 2018;97(34):e11316. \n                    https:\/\/doi.org\/10.1097\/MD.0000000000011316\n                    \n                  .","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"1098_CR95","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1212\/WNL.0000000000002285","volume":"86","author":"DE Payer","year":"2016","unstructured":"Payer DE, Guttman M, Kish SJ, Tong J, Adams JR, Rusjan P, et al. D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia. Neurology. 2016;86(3):224\u201330. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000002285\n                    \n                  .","journal-title":"Neurology"},{"issue":"Suppl 4","key":"1098_CR96","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/S1353-8020(09)70827-2","volume":"15","author":"A Berthet","year":"2009","unstructured":"Berthet A, Bezard E. Dopamine receptors and l-dopa-induced dyskinesia. Parkinsonism Relat Disord. 2009;15(Suppl 4):S8\u201312. \n                    https:\/\/doi.org\/10.1016\/S1353-8020(09)70827-2\n                    \n                  .","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"1098_CR97","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.parkreldis.2014.09.016","volume":"20","author":"N Giladi","year":"2014","unstructured":"Giladi N, Ghys L, Surmann E, Boroojerdi B, Jankovic J. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20(12):1345\u201351. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2014.09.016\n                    \n                  .","journal-title":"Parkinsonism Relat Disord"},{"issue":"Pt 11","key":"1098_CR98","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1093\/brain\/123.11.2297","volume":"123","author":"A Schrag","year":"2000","unstructured":"Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson\u2019s disease. A community-based study. Brain. 2000;123(Pt 11):2297\u2013305. \n                    https:\/\/doi.org\/10.1093\/brain\/123.11.2297\n                    \n                  .","journal-title":"Brain"},{"issue":"Pt 10","key":"1098_CR99","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/brain\/awu212","volume":"137","author":"SH Fox","year":"2014","unstructured":"Fox SH, Lang AE. \u2018Don\u2019t delay, start today\u2019: delaying levodopa does not delay motor complications. Brain. 2014;137(Pt 10):2628\u201330. \n                    https:\/\/doi.org\/10.1093\/brain\/awu212\n                    \n                  .","journal-title":"Brain"},{"issue":"Pt 10","key":"1098_CR100","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/brain\/awu195","volume":"137","author":"R Cilia","year":"2014","unstructured":"Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, et al. The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(Pt 10):2731\u201342. \n                    https:\/\/doi.org\/10.1093\/brain\/awu195\n                    \n                  .","journal-title":"Brain"},{"key":"1098_CR101","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/PROM.S29443","volume":"3","author":"N Hattori","year":"2012","unstructured":"Hattori N, Fujimoto K, Kondo T, Murata M, Stacy M. Patient perspectives on Parkinson\u2019s disease therapy in Japan and the United States: results of two patient surveys. Patient Relat Outcome Meas. 2012;3:31\u20138. \n                    https:\/\/doi.org\/10.2147\/PROM.S29443\n                    \n                  .","journal-title":"Patient Relat Outcome Meas"},{"issue":"4","key":"1098_CR102","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1212\/WNL.0000000000000050","volume":"82","author":"F Ory-Magne","year":"2014","unstructured":"Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology. 2014;82(4):300\u20137. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000000050\n                    \n                  .","journal-title":"Neurology"},{"issue":"3","key":"1098_CR103","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/mds.25321","volume":"28","author":"CG Goetz","year":"2013","unstructured":"Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, et al. Which dyskinesia scale best detects treatment response? Mov Disord. 2013;28(3):341\u20136. \n                    https:\/\/doi.org\/10.1002\/mds.25321\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"12","key":"1098_CR104","doi-asserted-by":"publisher","first-page":"e15298","DOI":"10.1371\/journal.pone.0015298","volume":"5","author":"H Sawada","year":"2010","unstructured":"Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, et al. Amantadine for dyskinesias in Parkinson\u2019s disease: a randomized controlled trial. PLoS One. 2010;5(12):e15298. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0015298\n                    \n                  .","journal-title":"PLoS One"},{"issue":"14","key":"1098_CR105","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/WNL.0b013e31824e8f0d","volume":"78","author":"G Hubsher","year":"2012","unstructured":"Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096\u20139. \n                    https:\/\/doi.org\/10.1212\/WNL.0b013e31824e8f0d\n                    \n                  .","journal-title":"Neurology"},{"issue":"12","key":"1098_CR106","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/mds.27131","volume":"32","author":"W Oertel","year":"2017","unstructured":"Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 3). Mov Disord. 2017;32(12):1701\u20139. \n                    https:\/\/doi.org\/10.1002\/mds.27131\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"2","key":"1098_CR107","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mdc3.12595","volume":"5","author":"SH Isaacson","year":"2018","unstructured":"Isaacson SH, Fahn S, Pahwa R, Tanner CM, Espay AJ, Trenkwalder C, et al. Parkinson\u2019s patients with dyskinesia switched from immediate release amantadine to open-label ADS-5102. Mov Disord Clin Pract. 2018;5(2):183\u201390. \n                    https:\/\/doi.org\/10.1002\/mdc3.12595\n                    \n                  .","journal-title":"Mov Disord Clin Pract"},{"issue":"6","key":"1098_CR108","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/mds.26159","volume":"30","author":"R Pahwa","year":"2015","unstructured":"Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASED Study). Mov Disord. 2015;30(6):788\u201395. \n                    https:\/\/doi.org\/10.1002\/mds.26159\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"3","key":"1098_CR109","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3233\/JPD-171134","volume":"7","author":"RA Hauser","year":"2017","unstructured":"Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, et al. ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 2 Study): interim results of an open-label safety study. J Parkinsons Dis. 2017;7(3):511\u201322. \n                    https:\/\/doi.org\/10.3233\/JPD-171134\n                    \n                  .","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"1098_CR110","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2169\/internalmedicine.52.8333","volume":"52","author":"H Utsumi","year":"2013","unstructured":"Utsumi H, Okuma Y, Kano O, Suzuki Y, Iijima M, Tomimitsu H, et al. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson\u2019s disease. Intern Med. 2013;52(3):325\u201332. \n                    https:\/\/doi.org\/10.2169\/internalmedicine.52.8333\n                    \n                  .","journal-title":"Intern Med"},{"issue":"7","key":"1098_CR111","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/mds.26585","volume":"31","author":"C Trenkwalder","year":"2016","unstructured":"Trenkwalder C, Stocchi F, Poewe W, Dronamraju N, Kenney C, Shah A, et al. Mavoglurant in Parkinson\u2019s patients with l-Dopa-induced dyskinesias: two randomized phase 2 studies. Mov Disord. 2016;31(7):1054\u20138. \n                    https:\/\/doi.org\/10.1002\/mds.26585\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"Pt 4","key":"1098_CR112","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/brain\/awu409","volume":"138","author":"P Svenningsson","year":"2015","unstructured":"Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, et al. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson\u2019s disease: a dose-finding study. Brain. 2015;138(Pt 4):963\u201373. \n                    https:\/\/doi.org\/10.1093\/brain\/awu409\n                    \n                  .","journal-title":"Brain"},{"issue":"8","key":"1098_CR113","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/mds.25366","volume":"28","author":"E Bezard","year":"2013","unstructured":"Bezard E, Tronci E, Pioli EY, Li Q, Porras G, Bjorklund A, et al. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord. 2013;28(8):1088\u201396. \n                    https:\/\/doi.org\/10.1002\/mds.25366\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"2","key":"1098_CR114","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/1545968311416990","volume":"26","author":"G Frazzitta","year":"2012","unstructured":"Frazzitta G, Bertotti G, Riboldazzi G, Turla M, Uccellini D, Boveri N, et al. Effectiveness of intensive inpatient rehabilitation treatment on disease progression in parkinsonian patients: a randomized controlled trial with 1-year follow-up. Neurorehabil Neural Repair. 2012;26(2):144\u201350. \n                    https:\/\/doi.org\/10.1177\/1545968311416990\n                    \n                  .","journal-title":"Neurorehabil Neural Repair"},{"issue":"2","key":"1098_CR115","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S1474-4422(11)70308-8","volume":"11","author":"MS Okun","year":"2012","unstructured":"Okun MS, Gallo BV, Mandybur G, Jagid J, Foote KD, Revilla FJ, et al. Subthalamic deep brain stimulation with a constant-current device in Parkinson\u2019s disease: an open-label randomised controlled trial. Lancet Neurol. 2012;11(2):140\u20139. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(11)70308-8\n                    \n                  .","journal-title":"Lancet Neurol"},{"issue":"22","key":"1098_CR116","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1056\/NEJMoa0907083","volume":"362","author":"KA Follett","year":"2010","unstructured":"Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med. 2010;362(22):2077\u201391. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0907083\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"1","key":"1098_CR117","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1212\/WNL.0b013e31825dcdc1","volume":"79","author":"FM Weaver","year":"2012","unstructured":"Weaver FM, Follett KA, Stern M, Luo P, Harris CL, Hur K, et al. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology. 2012;79(1):55\u201365. \n                    https:\/\/doi.org\/10.1212\/WNL.0b013e31825dcdc1\n                    \n                  .","journal-title":"Neurology"},{"issue":"7","key":"1098_CR118","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1205158","volume":"368","author":"WM Schuepbach","year":"2013","unstructured":"Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, et al. Neurostimulation for Parkinson\u2019s disease with early motor complications. N Engl J Med. 2013;368(7):610\u201322. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1205158\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"1","key":"1098_CR119","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(12)70264-8","volume":"12","author":"VJ Odekerken","year":"2013","unstructured":"Odekerken VJ, van Laar T, Staal MJ, Mosch A, Hoffmann CF, Nijssen PC, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson\u2019s disease (NSTAPS study): a randomised controlled trial. Lancet Neurol. 2013;12(1):37\u201344. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(12)70264-8\n                    \n                  .","journal-title":"Lancet Neurol"},{"issue":"8","key":"1098_CR120","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1212\/WNL.0000000000002401","volume":"86","author":"VJ Odekerken","year":"2016","unstructured":"Odekerken VJ, Boel JA, Schmand BA, de Haan RJ, Figee M, van den Munckhof P, et al. GPi vs STN deep brain stimulation for Parkinson disease: three-year follow-up. Neurology. 2016;86(8):755\u201361. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000002401\n                    \n                  .","journal-title":"Neurology"},{"issue":"1","key":"1098_CR121","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03866.x","volume":"20","author":"JJ Ferreira","year":"2013","unstructured":"Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, et al. Summary of the recommendations of the EFNS\/MDS-ES review on therapeutic management of Parkinson\u2019s disease. Eur J Neurol. 2013;20(1):5\u201315. \n                    https:\/\/doi.org\/10.1111\/j.1468-1331.2012.03866.x\n                    \n                  .","journal-title":"Eur J Neurol"},{"issue":"Suppl 14","key":"1098_CR122","doi-asserted-by":"publisher","first-page":"S290","DOI":"10.1002\/mds.20962","volume":"21","author":"G Kleiner-Fisman","year":"2006","unstructured":"Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006;21(Suppl 14):S290\u2013304.","journal-title":"Mov Disord"},{"issue":"2","key":"1098_CR123","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa\u2013carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141\u20139. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(13)70293-X\n                    \n                  .","journal-title":"Lancet Neurol"},{"issue":"4","key":"1098_CR124","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.26123","volume":"30","author":"HH Fernandez","year":"2015","unstructured":"Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, et al. Levodopa\u2013carbidopa intestinal gel in advanced Parkinson\u2019s disease: final 12-month, open-label results. Mov Disord. 2015;30(4):500\u20139. \n                    https:\/\/doi.org\/10.1002\/mds.26123\n                    \n                  .","journal-title":"Mov Disord"},{"issue":"4","key":"1098_CR125","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/mds.26528","volume":"31","author":"A Antonini","year":"2016","unstructured":"Antonini A, Fung VS, Boyd JT, Slevin JT, Hall C, Chatamra K, et al. Effect of levodopa\u2013carbidopa intestinal gel on dyskinesia in advanced Parkinson\u2019s disease patients. Mov Disord. 2016;31(4):530\u20137. \n                    https:\/\/doi.org\/10.1002\/mds.26528\n                    \n                  .","journal-title":"Mov Disord"},{"key":"1098_CR126","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.parkreldis.2017.02.020","volume":"38","author":"M Sensi","year":"2017","unstructured":"Sensi M, Cossu G, Mancini F, Pilleri M, Zibetti M, Modugno N, et al. Which patients discontinue? Issues on Levodopa\/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism Relat Disord. 2017;38:90\u20132. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2017.02.020\n                    \n                  .","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"1098_CR127","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/ene.12846","volume":"23","author":"A Merola","year":"2016","unstructured":"Merola A, Romagnolo A, Zibetti M, Bernardini A, Cocito D, Lopiano L. Peripheral neuropathy associated with levodopa\u2013carbidopa intestinal infusion: a long-term prospective assessment. Eur J Neurol. 2016;23(3):501\u20139. \n                    https:\/\/doi.org\/10.1111\/ene.12846\n                    \n                  .","journal-title":"Eur J Neurol"},{"issue":"6","key":"1098_CR128","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/ane.12783","volume":"136","author":"V Rispoli","year":"2017","unstructured":"Rispoli V, Simioni V, Capone JG, Golfre Andreasi N, Preda F, Sette E, et al. Peripheral neuropathy in 30 duodopa patients with vitamins B supplementation. Acta Neurol Scand. 2017;136(6):660\u20137. \n                    https:\/\/doi.org\/10.1111\/ane.12783\n                    \n                  .","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"1098_CR129","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/mus.25377","volume":"54","author":"G Devigili","year":"2016","unstructured":"Devigili G, Rinaldo S, Lettieri C, Eleopra R. Levodopa\/carbidopa intestinal gel therapy for advanced Parkinson disease: AN early toxic effect for small nerve fibers? Muscle Nerve. 2016;54(5):970\u20132. \n                    https:\/\/doi.org\/10.1002\/mus.25377\n                    \n                  .","journal-title":"Muscle Nerve"},{"issue":"9","key":"1098_CR130","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17(9):749\u201359. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(18)30239-4\n                    \n                  .","journal-title":"Lancet Neurol"},{"issue":"5","key":"1098_CR131","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/ane.12733","volume":"136","author":"E Dietrichs","year":"2017","unstructured":"Dietrichs E, Odin P. Algorithms for the treatment of motor problems in Parkinson\u2019s disease. Acta Neurol Scand. 2017;136(5):378\u201385. \n                    https:\/\/doi.org\/10.1111\/ane.12733\n                    \n                  .","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"1098_CR132","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/mdc3.12416","volume":"4","author":"P Barbosa","year":"2017","unstructured":"Barbosa P, Lees AJ, Magee C, Djamshidian A, Warner TT. A retrospective evaluation of the frequency of impulsive compulsive behaviors in Parkinson\u2019s disease patients treated with continuous waking day apomorphine pumps. Mov Disord Clin Pract. 2017;4(3):323\u20138. \n                    https:\/\/doi.org\/10.1002\/mdc3.12416\n                    \n                  .","journal-title":"Mov Disord Clin Pract"},{"key":"1098_CR133","unstructured":"Sunovion Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-130277) [press release]. Marlborough: Sunovion Pharmaceuticals; 2019. \n                    http:\/\/businesswire.com\/news\/home\/20190130005919\/en\/Sunovion-Receives-Complete-Response-Letter-FDA-Apomorphine\n                    \n                  . Accessed Feb 26, 2019."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01098-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01098-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01098-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,22]],"date-time":"2020-03-22T00:30:05Z","timestamp":1584837005000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01098-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,23]]},"references-count":133,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1098"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01098-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,23]]},"assertion":[{"value":"23 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors received no funding for this article from any entity in the public or private domains.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ver\u00f3nica Cabreira has received financial support to attend scientific meetings from Roche. Jo\u00e3o Massano received advisor honoraria from Bial, Merck Sharp and Dohme, and Zambon; he received financial support to speak at or attend meetings from Bial, Boston Scientific, GE Healthcare, Grunenthal, Medtronic, and Novartis. Patr\u00edcio Soares-da-Silva is employed by Bial\u2014Portela & C\u00aa, S.A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}